In addition, physiological elevations in the hypoxia-inducible factor-1 α (HIF-1 α) have been shown to allow adaptation of pancreatic cancer cells to hypoxic conditions, further mediating resistance to anti-VEGF therapies [42]. The gene discussed is VEGFA; the disease is familial pancreatic carcinoma.